Neural substrates and potential treatments for levodopa-induced dyskinesias in Parkinson's disease

Joseph R. Phillips, Abeer M. Eissa, Doaa H. Hewedi, Marjan Jahanshahi, Mohamed El-Gamal, Szabolcs Keri, Ahmed A. Moustafa*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)
22 Downloads (Pure)


Parkinson's disease (PD) is primarily a motor disorder that involves the gradual loss of motor function. Symptoms are observed initially in the extremities, such as hands and arms, while advanced stages of the disease can effect blinking, swallowing, speaking, and breathing. PD is a neurodegenerative disease, with dopaminergic neuronal loss occurring in the substantia nigra pars compacta, thus disrupting basal ganglia functions. This leads to downstream effects on other neurotransmitter systems such as glutamate, γ-aminobutyric acid, and serotonin. To date, one of the main treatments for PD is levodopa. While it is generally very effective, prolonged treatments lead to levodopa-induced dyskinesia (LID). LID encompasses a family of symptoms ranging from uncontrolled repetitive movements to sustained muscle contractions. In many cases, the symptoms of LID can cause more grief than PD itself. The purpose of this review is to discuss the possible clinical features, cognitive correlates, neural substrates, as well as potential psychopharmacological and surgical (including nondopaminergic and deep brain stimulation) treatments of LID.

Original languageEnglish
Pages (from-to)729-738
Number of pages10
JournalReviews in the Neurosciences
Issue number7
Publication statusPublished - 1 Oct 2016
Externally publishedYes


Dive into the research topics of 'Neural substrates and potential treatments for levodopa-induced dyskinesias in Parkinson's disease'. Together they form a unique fingerprint.

Cite this